Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 729 entries
Sorted by: Best Match Show Resources per page
Correction: Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[No authors listed]
PMID: 25587112
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):318. doi: 10.1158/1055-9965.EPI-14-1205.

No abstract available.

Cite
Correction: Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):318doi: 10.1158/1055-9965.EPI-14-1205.
(2015). Correction: Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 24(1), 318. https://doi.org/10.1158/1055-9965.EPI-14-1205
"Correction: Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 24,1 (2015): 318. doi: https://doi.org/10.1158/1055-9965.EPI-14-1205
Correction: Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):318. doi: 10.1158/1055-9965.EPI-14-1205. PMID: 25587112.
Copy Download .nbib Format: NLM
Correction: Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[No authors listed]
PMID: 25934835
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):880. doi: 10.1158/1055-9965.EPI-14-1404.

No abstract available.

Cite
Correction: Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev. 2015;24(5):880doi: 10.1158/1055-9965.EPI-14-1404.
(2015). Correction: Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 24(5), 880. https://doi.org/10.1158/1055-9965.EPI-14-1404
"Correction: Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 24,5 (2015): 880. doi: https://doi.org/10.1158/1055-9965.EPI-14-1404
Correction: Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):880. doi: 10.1158/1055-9965.EPI-14-1404. PMID: 25934835.
Copy Download .nbib Format: NLM
Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread?.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Weiss NS.
PMID: 18559544
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1297-9. doi: 10.1158/1055-9965.EPI-08-0144.

No abstract available.

Cite
Weiss NS. Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread?. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1297-9doi: 10.1158/1055-9965.EPI-08-0144.
Weiss, N. S. (2008). Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread?. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 17(6), 1297-9. https://doi.org/10.1158/1055-9965.EPI-08-0144
Weiss, Noel S. "Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread?." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 17,6 (2008): 1297-9. doi: https://doi.org/10.1158/1055-9965.EPI-08-0144
Weiss NS. Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread?. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1297-9. doi: 10.1158/1055-9965.EPI-08-0144. PMID: 18559544.
Copy Download .nbib Format: NLM
Addressing disparities in colorectal cancer burden: how far could equal health care access bring us?.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Reuland DS, Pignone MP.
PMID: 22426146
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):707-8. doi: 10.1158/1055-9965.EPI-12-0287. Epub 2012 Mar 16.

No abstract available.

Cite
Reuland DS, Pignone MP. Addressing disparities in colorectal cancer burden: how far could equal health care access bring us?. Cancer Epidemiol Biomarkers Prev. 2012;21(5):707-8doi: 10.1158/1055-9965.EPI-12-0287.
Reuland, D. S., & Pignone, M. P. (2012). Addressing disparities in colorectal cancer burden: how far could equal health care access bring us?. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 21(5), 707-8. https://doi.org/10.1158/1055-9965.EPI-12-0287
Reuland, Daniel S, and Pignone, Michael P. "Addressing disparities in colorectal cancer burden: how far could equal health care access bring us?." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 21,5 (2012): 707-8. doi: https://doi.org/10.1158/1055-9965.EPI-12-0287
Reuland DS, Pignone MP. Addressing disparities in colorectal cancer burden: how far could equal health care access bring us?. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):707-8. doi: 10.1158/1055-9965.EPI-12-0287. Epub 2012 Mar 16. PMID: 22426146; PMCID: PMC5819011.
Copy Download .nbib Format: NLM
Tobacco use in the oncology setting: advancing clinical practice and research.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Gritz ER, Toll BA, Warren GW.
PMID: 24420982
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):3-9. doi: 10.1158/1055-9965.EPI-13-0896.

Although tobacco is a well-established causal agent for many human cancers, less emphasis has been placed on translating this evidence by evaluating the effects of continued tobacco use after a cancer diagnosis. A broad assessment of the effects of...

Cite
Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiol Biomarkers Prev. 2014;23(1):3-9doi: 10.1158/1055-9965.EPI-13-0896.
Gritz, E. R., Toll, B. A., & Warren, G. W. (2014). Tobacco use in the oncology setting: advancing clinical practice and research. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23(1), 3-9. https://doi.org/10.1158/1055-9965.EPI-13-0896
Gritz, Ellen R, et al. "Tobacco use in the oncology setting: advancing clinical practice and research." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 23,1 (2014): 3-9. doi: https://doi.org/10.1158/1055-9965.EPI-13-0896
Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):3-9. doi: 10.1158/1055-9965.EPI-13-0896. PMID: 24420982; PMCID: PMC3893715.
Copy Download .nbib Format: NLM
Assessing the value of patient navigation for completing cancer screening.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Byers T.
PMID: 23045535
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1618-9. doi: 10.1158/1055-9965.EPI-12-0964.

No abstract available.

Cite
Byers T. Assessing the value of patient navigation for completing cancer screening. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1618-9doi: 10.1158/1055-9965.EPI-12-0964.
Byers, T. (2012). Assessing the value of patient navigation for completing cancer screening. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 21(10), 1618-9. https://doi.org/10.1158/1055-9965.EPI-12-0964
Byers, Tim. "Assessing the value of patient navigation for completing cancer screening." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 21,10 (2012): 1618-9. doi: https://doi.org/10.1158/1055-9965.EPI-12-0964
Byers T. Assessing the value of patient navigation for completing cancer screening. Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1618-9. doi: 10.1158/1055-9965.EPI-12-0964. PMID: 23045535.
Copy Download .nbib Format: NLM
Follow-up to abnormal cancer screening tests: considering the multilevel context of care.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Zapka JM, Edwards HM, Chollette V, Taplin SH.
PMID: 25073625
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1965-73. doi: 10.1158/1055-9965.EPI-14-0454. Epub 2014 Jul 29.

The call for multilevel interventions to improve the quality of follow-up to abnormal cancer screening has been out for a decade, but published work emphasizes individual approaches, and conceptualizations differ regarding the definition of levels. To investigate the scope...

Cite
Zapka JM, Edwards HM, Chollette V, et al. Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1965-73doi: 10.1158/1055-9965.EPI-14-0454.
Zapka, J. M., Edwards, H. M., Chollette, V., & Taplin, S. H. (2014). Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23(10), 1965-73. https://doi.org/10.1158/1055-9965.EPI-14-0454
Zapka, Jane M, et al. "Follow-up to abnormal cancer screening tests: considering the multilevel context of care." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 23,10 (2014): 1965-73. doi: https://doi.org/10.1158/1055-9965.EPI-14-0454
Zapka JM, Edwards HM, Chollette V, Taplin SH. Follow-up to abnormal cancer screening tests: considering the multilevel context of care. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1965-73. doi: 10.1158/1055-9965.EPI-14-0454. Epub 2014 Jul 29. PMID: 25073625; PMCID: PMC4191903.
Copy Download .nbib Format: NLM
The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

El-Zein RA, Lopez MS, D'Amelio AM, Liu M, Munden RF, Christiani D, Su L, Tejera-Alveraz P, Zhai R, Spitz MR, Etzel CJ.
PMID: 25172871
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2462-70. doi: 10.1158/1055-9965.EPI-14-0462. Epub 2014 Aug 29.

BACKGROUND: There is an urgent need to improve lung cancer outcome by identifying and validating markers of risk. We previously reported that the cytokinesis-blocked micronucleus assay (CBMN) is a strong predictor of lung cancer risk. Here, we validate our...

Cite
El-Zein RA, Lopez MS, D'Amelio AM, et al. The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2462-70doi: 10.1158/1055-9965.EPI-14-0462.
El-Zein, R. A., Lopez, M. S., D'Amelio, A. M., Liu, M., Munden, R. F., Christiani, D., Su, L., Tejera-Alveraz, P., Zhai, R., Spitz, M. R., & Etzel, C. J. (2014). The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23(11), 2462-70. https://doi.org/10.1158/1055-9965.EPI-14-0462
El-Zein, Randa A, et al. "The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 23,11 (2014): 2462-70. doi: https://doi.org/10.1158/1055-9965.EPI-14-0462
El-Zein RA, Lopez MS, D'Amelio AM, Liu M, Munden RF, Christiani D, Su L, Tejera-Alveraz P, Zhai R, Spitz MR, Etzel CJ. The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2462-70. doi: 10.1158/1055-9965.EPI-14-0462. Epub 2014 Aug 29. PMID: 25172871; PMCID: PMC4487661.
Copy Download .nbib Format: NLM
Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Goding Sauer A, Siegel RL, Jemal A, Fedewa SA.
PMID: 30944145
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):629-642. doi: 10.1158/1055-9965.EPI-18-1169.

Overall cancer death rates in the United States have declined since 1990. The decline could be accelerated by eliminating socioeconomic and racial disparities in major risk factors and screening utilization. We provide an updated review of the prevalence of...

Cite
Goding Sauer A, Siegel RL, Jemal A, et al. Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. Cancer Epidemiol Biomarkers Prev. 2019;28(4):629-642doi: 10.1158/1055-9965.EPI-18-1169.
Goding Sauer, A., Siegel, R. L., Jemal, A., & Fedewa, S. A. (2019). Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 28(4), 629-642. https://doi.org/10.1158/1055-9965.EPI-18-1169
Goding Sauer, Ann, et al. "Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 28,4 (2019): 629-642. doi: https://doi.org/10.1158/1055-9965.EPI-18-1169
Goding Sauer A, Siegel RL, Jemal A, Fedewa SA. Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):629-642. doi: 10.1158/1055-9965.EPI-18-1169. PMID: 30944145.
Copy Download .nbib Format: NLM
Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Myers RE, Stello B, Daskalakis C, Sifri R, González ET, DiCarlo M, Johnson MB, Hegarty SE, Shaak K, Rivera A, Gordils-Molina L, Petrich A, Careyva B, de-Ortiz R, Diaz L.
PMID: 30333221
Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):384-391. doi: 10.1158/1055-9965.EPI-18-0260. Epub 2018 Oct 17.

BACKGROUND: Effective strategies are needed to raise colorectal cancer screening rates among Hispanics.METHODS: We surveyed and randomized 400 Hispanic primary care patients either to a Decision Support and Navigation Intervention (DSNI) Group (RESULTS: Screening adherence was significantly higher in...

Cite
Myers RE, Stello B, Daskalakis C, et al. Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients. Cancer Epidemiol Biomarkers Prev. 2018;28(2):384-391doi: 10.1158/1055-9965.EPI-18-0260.
Myers, R. E., Stello, B., Daskalakis, C., Sifri, R., González, E. T., DiCarlo, M., Johnson, M. B., Hegarty, S. E., Shaak, K., Rivera, A., Gordils-Molina, L., Petrich, A., Careyva, B., de-Ortiz, R., & Diaz, L. (2019). Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 28(2), 384-391. https://doi.org/10.1158/1055-9965.EPI-18-0260
Myers, Ronald E, et al. "Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 28,2 (2019): 384-391. doi: https://doi.org/10.1158/1055-9965.EPI-18-0260
Myers RE, Stello B, Daskalakis C, Sifri R, González ET, DiCarlo M, Johnson MB, Hegarty SE, Shaak K, Rivera A, Gordils-Molina L, Petrich A, Careyva B, de-Ortiz R, Diaz L. Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients. Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):384-391. doi: 10.1158/1055-9965.EPI-18-0260. Epub 2018 Oct 17. PMID: 30333221.
Copy Download .nbib Format: NLM
Longitude Position in a Time Zone and Cancer Risk-Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Grant WB.
PMID: 30181321
Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1110. doi: 10.1158/1055-9965.EPI-17-1125.

No abstract available.

Cite
Grant WB. Longitude Position in a Time Zone and Cancer Risk-Letter. Cancer Epidemiol Biomarkers Prev. 2018;27(9):1110doi: 10.1158/1055-9965.EPI-17-1125.
Grant, W. B. (2018). Longitude Position in a Time Zone and Cancer Risk-Letter. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 27(9), 1110. https://doi.org/10.1158/1055-9965.EPI-17-1125
Grant, William B. "Longitude Position in a Time Zone and Cancer Risk-Letter." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 27,9 (2018): 1110. doi: https://doi.org/10.1158/1055-9965.EPI-17-1125
Grant WB. Longitude Position in a Time Zone and Cancer Risk-Letter. Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1110. doi: 10.1158/1055-9965.EPI-17-1125. PMID: 30181321.
Copy Download .nbib Format: NLM
Population-Based Precision Cancer Screening-Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Olsen KS, Lund E.
PMID: 28506964
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):975. doi: 10.1158/1055-9965.EPI-16-0903. Epub 2017 May 15.

No abstract available.

Cite
Olsen KS, Lund E. Population-Based Precision Cancer Screening-Letter. Cancer Epidemiol Biomarkers Prev. 2017;26(6):975doi: 10.1158/1055-9965.EPI-16-0903.
Olsen, K. S., & Lund, E. (2017). Population-Based Precision Cancer Screening-Letter. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 26(6), 975. https://doi.org/10.1158/1055-9965.EPI-16-0903
Olsen, Karina Standahl, and Lund, Eiliv. "Population-Based Precision Cancer Screening-Letter." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 26,6 (2017): 975. doi: https://doi.org/10.1158/1055-9965.EPI-16-0903
Olsen KS, Lund E. Population-Based Precision Cancer Screening-Letter. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):975. doi: 10.1158/1055-9965.EPI-16-0903. Epub 2017 May 15. PMID: 28506964.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 729 entries